文献速递重症综合管理与镇静镇痛

改良中线导管与中心静脉导管在内科重症监护病房应用的真实世界研究

[A real-world study on the application of modified midline catheter and central venous catheter in medical intensive care unit].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论ARDS、心血管疾病和肿瘤患者更常用改良中线导管,需用血管活性药物时以中心静脉导管为主;改良中线导管和留置时间≥12天是拔管的独立危险因素,但其总体并发症发生率低于中心静脉导管。

该单中心回顾性队列连续纳入2023年1月1日至2024年7月31日在中南大学湘雅三医院内科重症监护病房置入改良中线导管或中心静脉导管的274例成人患者(改良中线导管52例、中心静脉导管222例),比较两种导管在不同基础疾病下的选择、置管后实际应用、导管相关并发症及住院结局。结果显示,ARDS、心血管疾病、肿瘤患者中改良中线导管使用率更高,需输注血管活性药物时改良中线导管使用率更低;改良中线导管组留置时间≥12天比例更高,部分或完全拔管发生率更高(36.5%比5.4%),但穿刺点渗液、穿刺点皮肤过敏、深静脉血栓发生率更低。多因素Logistic回归显示使用改良中线导管(OR=8.518,95%CI 3.710-19.560,P<0.001)和留置时间≥12天(OR=3.133,95%CI 1.297-7.567,P=0.011)是拔管的独立危险因素。作者认为,在多数临床场景中改良中线导管可作为中心静脉导管的常规替代,前提是采取措施防止拔管。

要点

  • ARDS患者中改良中线导管使用率92.3%(48/52)高于中心静脉导管70.3%(156/222),心血管疾病84.6%(44/52)高于54.5%(121/222),肿瘤30.8%(16/52)高于17.1%(38/222),均P<0.05。
  • 需输注血管活性药物时改良中线导管使用率57.7%(30/52)低于中心静脉导管79.7%(177/222),P<0.05。
  • 改良中线导管组部分或完全拔管发生率36.5%(19/52)高于中心静脉导管组5.4%(12/222),P<0.05;留置时间≥12天比例32.7%(17/52)高于13.5%(30/222),P<0.05。
  • 改良中线导管组穿刺点渗液1.9%(1/52)低于22.1%(49/222)、穿刺点皮肤过敏0%(0/52)低于20.7%(46/222)、深静脉血栓3.8%(2/52)低于16.7%(37/222),均P<0.05;发生3种及以上并发症比例5.8%(3/52)低于17.6%(39/222),P<0.05。
  • 多因素Logistic回归显示,使用改良中线导管(OR=8.518,95%CI 3.710-19.560,P<0.001)和留置时间≥12天(OR=3.133,95%CI 1.297-7.567,P=0.011)是拔管的独立危险因素。

适用人群与场景

  • 中南大学湘雅三医院内科重症监护病房收治的成人患者
  • 2023年1月1日至2024年7月31日期间置入改良中线导管或中心静脉导管的患者

研究设计与关键结果

  • 单中心回顾性队列研究,连续纳入274例成人内科重症监护病房患者,其中改良中线导管组52例、中心静脉导管组222例,比较两组导管选择、置管后应用、导管相关并发症及住院结局。
  • ARDS患者中改良中线导管使用率92.3%(48/52)高于中心静脉导管70.3%(156/222),心血管疾病84.6%(44/52)高于54.5%(121/222),肿瘤30.8%(16/52)高于17.1%(38/222),均P<0.05;需输注血管活性药物时改良中线导管使用率57.7%(30/52)低于中心静脉导管79.7%(177/222),P<0.05。
  • 改良中线导管组留置时间≥12天比例32.7%(17/52)高于中心静脉导管组13.5%(30/222),P<0.05;两组其他基础疾病、静脉通路用途、穿刺及置管期间INR和PLT、ICU住院时间、总住院时间及院内死亡率差异均无统计学意义。
  • 改良中线导管组部分或完全拔管发生率36.5%(19/52)高于中心静脉导管组5.4%(12/222),P<0.05;穿刺点渗液1.9%(1/52)低于22.1%(49/222)、穿刺点皮肤过敏0%(0/52)低于20.7%(46/222)、深静脉血栓3.8%(2/52)低于16.7%(37/222),均P<0.05;发生3种及以上并发症比例5.8%(3/52)低于17.6%(39/222),P<0.05。
  • 多因素Logistic回归显示,使用改良中线导管(OR=8.518,95%CI 3.710-19.560,P<0.001)和留置时间≥12天(OR=3.133,95%CI 1.297-7.567,P=0.011)是拔管的独立危险因素。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,改良中线导管在多数临床场景中可作为中心静脉导管的常规替代,前提是采取措施防止拔管。
  • 对ARDS、心血管疾病和肿瘤患者,本研究中改良中线导管使用率更高;需输注血管活性药物时以中心静脉导管为主。
  • 使用改良中线导管和留置时间≥12天是拔管的独立危险因素,提示对该类患者需关注导管拔管风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the differences in indwelling duration, clinical scenarios, and complications between the modified midline catheter (MMC) and the central venous catheter (CVC) in the treatment of patients in the medical intensive care unit (ICU) and the risk factors for complications based on real-world data.

METHODS: A retrospective cohort study was conducted. The adult patients admitted to the medical ICU of the Third Xiangya Hospital of Central South University and had undergone placement of either a MMC or a CVC between January 1, 2023, and July 31, 2024, were consecutively enrolled by querying the hospital's electronic medical record system. Based on the type of catheter inserted, the patients were divided into the MMC group and the CVC group. The two groups were compared regarding the selection of catheters in the context of different underlying diseases, the actual clinical application after catheterization, catheter-related complications, the international normalized ratio (INR) and platelet count (PLT) during puncture and catheterization, the length of ICU stay, total length of hospital stay, catheter indwelling duration, and mortality during hospitalization. Multivariate Logistic regression analysis was employed to identify independent risk factors for catheter removal.

RESULTS: Among the 274 patients, 52 received a MMC and 222 received a CVC. The utilization rate of MMC was significantly higher than that of CVC in patients with acute respiratory distress syndrome (ARDS), cardiovascular disease, and cancer [ARDS: 92.3% (48/52) vs. 70.3% (156/222), cardiovascular disease: 84.6% (44/52) vs. 54.5% (121/222), cancer: 30.8% (16/52) vs. 17.1% (38/222), all P < 0.05]. However, the use of MMC was significantly lower than CVC when vasoactive drug infusion was required [57.7% (30/52) vs. 79.7% (177/222), P < 0.05]. A significantly higher proportion of patients in the MMC group had a catheter indwelling time ≥ 12 days as compared with the CVC group [32.7% (17/52) vs. 13.5% (30/222), P < 0.05]. There were no statistically significant differences in other underlying diseases, venous access usage, INR and PLT during puncture and catheterization, length of ICU stay, total length of hospital stay, and in-hospital mortality of patients between the two groups. Regarding catheter-related complications, although the incidence of partial or complete catheter removal in the MMC group was significantly higher than that in the CVC group [36.5% (19/52) vs. 5.4% (12/222), P < 0.05], the incidence of puncture site fluid leakage, puncture site skin allergy, and deep vein thrombosis were significantly lower than those in the CVC group [puncture site fluid leakage: 1.9% (1/52) vs. 22.1% (49/222), puncture site skin allergy: 0% (0/52) vs. 20.7% (46/222), deep vein thrombosis: 3.8% (2/52) vs. 16.7% (37/222), all P < 0.05]. Furthermore, the proportion of patients experiencing three or more types of complications in the MMC group was significantly lower than that in the CVC group [5.8% (3/52) vs. 17.6% (39/222), P < 0.05]. Multivariate Logistic regression analysis of risk factors for catheter removal identified the use of a MMC [odds ratio (OR) = 8.518, 95% confidence interval (95%CI) was 3.710-19.560, P < 0.001] and a catheter indwelling time ≥ 12 days (OR = 3.133, 95%CI was 1.297-7.567, P = 0.011) as independent risk factors.

CONCLUSIONS: MMC was more frequently used in patients with ARDS, cardiovascular disease, and cancer, whereas CVC was primarily employed for vasoactive drug infusion. The use of MMC and a longer indwelling time were identified as independent risk factors for catheter removal. Despite a higher removal rate, the overall incidence of complications was significantly lower with MMC than with CVC. These findings suggest that MMC could serve as a routine alternative to CVC in most of clinical scenarios, provided that measures are implemented to prevent removal.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Long G, Wang Z, Peng H, et al. [A real-world study on the application of modified midline catheter and central venous catheter in medical intensive care unit]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41331891. doi:10.3760/cma.j.cn121430-20250317-00252

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。